Vitamin D: A Statistical Error in the Recommended Intake, and Why a Blood Level Is Not the Same as a Benefit
Executive summary
The public recommended intake for vitamin D — 600 IU (international units) per day for most adults, 800 IU from the age of 71 — was set by the Institute of Medicine, whose figures inform health authorities across North America and, indirectly, much of the world. It was intended to raise blood 25-hydroxyvitamin D, written 25(OH)D and read aloud as "25 hydroxy D", to at least 50 nmol/L (equivalently 20 ng/mL) in 97.5% of the population (Ref 1).
A short 2014 analysis showed that the calculation behind this figure contained a genuine statistical error: it treated "97.5% of the study averages" as if it meant "97.5% of individuals". Read correctly, 600 IU per day would put only the average person, not the great majority, near the target (Ref 2).
The same paper estimated that reaching 50 nmol/L in 97.5% of individuals might require something like 8,895 IU per day. The authors themselves cautioned that this number lies far beyond the doses that were actually studied and should be read as an illustration of the direction of the error, not as a dosing instruction (Ref 2). An independent group confirmed the underlying mistake (Ref 3); a later analysis put the figure much lower and showed it depends heavily on body weight (Ref 4).
Reaching a blood number is not the same as gaining a health outcome. Large randomised trials of supplementation — VITAL and D-Health — found no reduction in cancer, cardiovascular events, fractures, or death in generally healthy adults who were not selected for deficiency (Ref 6, Ref 7, Ref 8).
Genetic evidence suggests the risk attached to low vitamin D is real but concentrated in genuine deficiency: the benefit is in correcting a low level, not in pushing an already-adequate level higher (Ref 9). The expert guidelines themselves have moved over the past decade and still disagree with one another (Ref 5, Ref 10, Ref 11).
I did take very high-dose vitamin D myself for several years without apparent harm. That is a single anecdote, it sat above the official upper limit, and it is not a recommendation for anyone else.
My own preference is to prioritise the routes the body evolved to use — sensible sunlight and animal foods such as oily fish, egg yolks, and liver — and to correct genuine deficiency thoughtfully, rather than to treat a laboratory target as a goal in its own right. I declare my interests, and the limits of my confidence, below.
Introduction
Vitamin D occupies an unusual position in public health. It is the subject of confident official numbers — an intake to aim for, a blood level to reach — and, at the same time, of a large and often contradictory research literature. My aim in this piece is narrow and, I hope, defensible: to look at where the most quoted number, the recommended intake, actually comes from; to show that its derivation contained a real and independently confirmed error; and then to be equally honest about what that error does and does not license us to conclude. It is easy to move from "the recommendation was miscalculated" to "everyone is dangerously deficient and should take large doses". The first statement is well supported. The second does not follow from it, and the trial evidence does not support it.
I should declare my interests plainly. I run a private clinic and I offer paid consultations, so I have a commercial interest in people valuing clinical reasoning of the kind set out here. I sell no vitamin D product and recommend no brand. I also hold a stated dietary bias: I lean towards animal-source nutrition, and readers should weigh what follows in that light. On qualifications, so the reader knows the lens: I originally trained in dentistry, then in dermatology, and separately in anti-aging medicine and in metabolic medicine. None of that makes me right. It shapes which questions I ask.
One general point of method before the detail. A great deal of nutritional advice is built on reference ranges and target numbers whose origins are rarely examined. When a guideline states that a level "should" be a particular figure, it is worth asking where that figure came from, which people were studied to produce it, and whether the reasoning survives scrutiny. Vitamin D turns out to be an unusually clean example of why that habit matters.
What vitamin D actually is
Calling it a vitamin is slightly misleading. A vitamin, strictly, is something you must obtain from the diet because the body cannot make it. Vitamin D is largely made by the body itself: ultraviolet B light striking the skin converts a cholesterol-derived molecule into vitamin D3, which the liver then converts to 25(OH)D — the circulating form measured in blood tests — and the kidney activates further into the hormone that acts on tissues (Ref 12). In other words it behaves more like a hormone the body manufactures on demand than like a nutrient imported through food. A useful analogy is that the body is less a shopper buying a finished product and more a workshop building its own tool when the raw material, sunlight, is available.
This matters for everything that follows, because it means there are two quite different ways to raise vitamin D — through the skin, which is regulated, and through the mouth as a supplement, which is not — and because the blood test everyone quotes, 25(OH)D, is a storage marker rather than a direct measure of what the active hormone is doing in your tissues.
Where the "600 IU" number comes from — and the error inside it
The recommended intake most people have met is the Institute of Medicine's Recommended Dietary Allowance: the intake judged sufficient to meet the requirements of 97.5% of healthy people. For vitamin D that was set at 600 IU per day for those aged 1 to 70, and 800 IU thereafter, chosen to achieve a blood 25(OH)D of at least 50 nmol/L (20 ng/mL) in that same 97.5% of the population, on the basis of bone health (Ref 1).
To derive it, the committee deliberately used supplementation studies conducted in winter and at high latitudes, so that sunlight would contribute as little as possible and the effect of the dose alone could be seen (Ref 1, Ref 2). They plotted blood level against dose across those studies and read off the intake that corresponded to the lower edge of the range.
Here is the error, and it is worth stating precisely because it is specific rather than rhetorical. The committee calculated the lower confidence limit of the study averages — and then interpreted it as if it described individuals. A 2014 letter in Nutrients pointed out that "97.5% of study averages lie above this line" is a completely different statement from "97.5% of individuals lie above this line", because individual people vary far more than the averages of whole studies do (Ref 2). The everyday version: if you take the average exam mark of each of thirty classes, those class averages cluster tightly together; the individual pupils inside those classes are spread much more widely. Reading a number that describes the clustered class averages and assuming it describes the spread-out pupils will mislead you, and it will mislead you in a predictable direction — towards a figure that is too low.
Corrected, the same data implied that 600 IU per day would only get 97.5% of individuals above roughly 27 nmol/L, not 50 (Ref 2). And to actually reach 50 nmol/L in 97.5% of individuals, the authors' regression pointed to something on the order of 8,895 IU per day.
That figure has since been quoted widely, so it deserves careful handling. The authors were explicit that it "is far beyond the range of studied doses", that "caution is warranted when interpreting this estimate", and that it exceeds the official tolerable upper intake of 4,000 IU per day (Ref 2). In other words, the headline number is an extrapolation the authors themselves flagged as unreliable in magnitude. What is robust is the direction and the existence of the mistake, not the precise size of the correction. An independent group — including researchers who had spent careers on vitamin D — wrote in to confirm that the statistical reasoning was indeed wrong and reached the same conclusion using a separate cohort (Ref 3). A later analysis by the original authors, drawing on more than a hundred studies and nearly fourteen thousand people, put the intake needed to reach 50 nmol/L in most people closer to around 3,000 IU per day, rising with body weight to markedly more in people with obesity, and argued that a single population-wide allowance is neither desirable nor feasible given how much individuals differ (Ref 4).
So the faithful summary is this. The specific arithmetic behind a very widely used recommendation was demonstrably wrong, in a way two independent groups agree on, and it understated the intake needed to hit its own blood-level target. That is a genuine and somewhat remarkable finding, and it is a good reason to treat reference numbers as arguments to be examined rather than facts to be memorised. It is not, by itself, a reason to swallow nine thousand units a day.
A marker is not an outcome
This is the point where honesty requires me to slow my own argument down, including where I have made it myself. Everything above concerns a blood marker, 25(OH)D, and the intake needed to move it. Whether moving that marker in an already-healthy person changes anything they care about — living longer, breaking fewer bones, avoiding cancer or heart disease — is a separate question, and it has been tested directly.
The largest such test, the VITAL trial, randomised nearly 26,000 adults in the United States to 2,000 IU of vitamin D per day or placebo. Over about five years it found no reduction in the risk of invasive cancer of any type and no reduction in major cardiovascular events, and it recorded no excess of hypercalcaemia in the vitamin D group (Ref 6). A dedicated analysis of the same trial found no reduction in fractures — total, non-vertebral, or hip — among these generally healthy older adults, and no benefit even in the subgroup who started with lower blood levels (Ref 7). The separate Australian D-Health trial, giving 60,000 IU monthly to more than 21,000 older people for five years, found no reduction in overall mortality; if anything, its exploratory analyses raised a cautionary signal for cancer death, leading the authors to invoke the precautionary principle against routine high-dose supplementation in people who are already replete (Ref 8).
The honest reading of these trials needs its own caveat, and it cuts both ways. Each of them enrolled largely vitamin-D-replete populations who were not selected for deficiency (Ref 6, Ref 7). So they are excellent tests of one specific policy — "give extra vitamin D to broadly healthy people regardless of their level" — and that policy failed. They are weaker tests of a different question: "does correcting genuine, symptomatic deficiency help?" A trial in which most participants are already adequate cannot easily show benefit from topping them up, in the same way that filling an already-full tank tells you nothing about how far an empty car could have gone. The blood level is a fuel gauge; a full gauge confirms the tank is not empty, but adding fuel past full does not extend the journey.
Genetic evidence helps square the circle. A Mendelian randomisation study in over 300,000 UK Biobank participants — an approach that uses inherited differences in vitamin D to approximate a lifelong natural experiment, and so is less prone to the confounding that plagues observational data — found that the relationship between vitamin D and death is L-shaped: risk falls steeply as low levels rise towards about 50 nmol/L, and then flattens (Ref 9). That is a coherent story. Genuine deficiency appears genuinely harmful; correcting it plausibly matters; pushing an already-adequate level higher does little. It reconciles the observational alarm about "widespread deficiency" with the null supplementation trials, and it is, to my mind, the most defensible current position.
The guidelines have been arguing with themselves
If the science were settled, the official bodies would agree. They do not, and the disagreement is instructive rather than embarrassing.
In 2011 the Endocrine Society issued a guideline that leant towards higher intakes and higher target levels than the Institute of Medicine, and recommended measuring 25(OH)D in people at risk of deficiency. Even then, it stated that there was not sufficient evidence to screen people who are not at risk, nor to prescribe vitamin D for cardiovascular protection (Ref 5). The Institute of Medicine, for its part, had already warned in the opposite direction: that the prevalence of vitamin D "inadequacy" had been overestimated, that higher blood levels were not consistently linked to greater benefit, that some outcomes showed a U-shaped curve with risk at both low and high levels, and that laboratory reference ranges urgently needed reassessing to avoid both under- and over-treatment (Ref 1).
By 2024 the pendulum had swung again. The Endocrine Society's newer evidence review, built on randomised trials rather than associations, found little effect of supplementation on most outcomes in healthy adults aged 19 to 74, a small mortality benefit only in those over 75, a reduction in progression from prediabetes to diabetes, and a signal that high-dose intermittent dosing may increase falls compared with lower daily doses. It found no trials that established the benefit of screening the general population with a 25(OH)D test at all (Ref 10). That shift did not go unchallenged: leading vitamin D researchers argued that confining the evidence to randomised trials discards a large body of association data on non-skeletal benefits (Ref 11). I do not think this argument is close to resolved, and where the optimal target level sits — if a single one exists — is something on which I am still collecting data rather than offering you a firm number.
On taking very high doses — my own experiment, and why it is not advice
For transparency, and because I have discussed it publicly before, I will state my own history. For a period of years I took vitamin D at doses well above the official upper limit, alongside vitamin K2, and experienced no ill effects that I could detect. I set this out because it is true and because concealing it would be its own kind of dishonesty. But I want to be careful about what it is worth, because a personal story is the weakest form of evidence there is, and I would rather you learned the reasoning than copied the behaviour.
That was many times the official tolerable upper intake of 4,000 IU per day and far above anything tested in the trials above. Vitamin D toxicity is real: because it is fat-soluble it accumulates, and the principal danger is hypercalcaemia — a rise in blood calcium that can damage the kidneys and other organs — generally described once blood levels climb above roughly 250 nmol/L (Ref 14). The reason we lean on case reports for this, rather than clean dose-response data, is that deliberately poisoning volunteers to find the threshold would be unethical (Ref 15). And those case reports show how idiosyncratic the response can be: one published patient reached a 25(OH)D of 746 ng/mL through a dosing error yet had normal blood calcium and no symptoms (Ref 15). That someone can tolerate an extreme level tells you about the width of human variation; it tells you nothing about whether you would be the person who is fine or the person in the next report who is not. I cannot see you through a screen, I do not know your kidney function or your calcium handling, and the sensible reading of the toxicity literature is caution, not reassurance.
My rationale for the co-administered K2 was mechanistic, and here the biochemistry is well established rather than speculative. Vitamin K is the cofactor that gamma-carboxylates a family of calcium-handling proteins: it activates osteocalcin, which helps deposit calcium into the bone matrix, and matrix Gla protein, which inhibits the deposition of calcium in arterial walls (Ref 16, Ref 18, Ref 19). Adequate vitamin K therefore helps steer calcium toward bone and away from blood vessels, which is exactly the concern when taking large amounts of vitamin D, and low vitamin K activity tracks with arterial stiffness and vascular calcification. It is a reasonable hypothesis that pairing the two might steer calcium sensibly. But I should apply my own standard here: when this was tested directly, a randomised trial of vitamin K2 plus vitamin D in men with existing aortic-valve calcification improved the relevant biochemical marker yet did not slow the calcification itself over two years (Ref 17). So the mechanism is plausible and the co-factor logic is defensible, but "plausible mechanism" is not "proven protection", and I hold the K2 rationale as a reasonable hedge rather than an established safeguard. If you are already taking prescribed high-dose vitamin D and are minded to change anything, speak to your prescriber before you do — that is a conversation to have with the clinician who knows your bloods, not a decision to make from an article.
Sunlight and food first
If vitamin D is something the body was designed to make from sunlight, the obvious first question is not "which supplement" but "why has the ordinary supply fallen short". Skin synthesis depends on ultraviolet B reaching the skin, which varies with latitude, season, time of day, and skin pigmentation; the further from the equator, the darker the winter, and the more melanin in the skin, the less is made from a given amount of sun (Ref 12). This is also why the Institute of Medicine built its recommendation on people with minimal sun in the first place (Ref 1). There is a neat piece of physiology worth knowing: cutaneous production has a built-in ceiling, because the same sunlight that makes vitamin D in the skin also breaks down any excess, so ordinary sun exposure does not cause toxicity — rather like a kettle that switches itself off at the boil. Oral megadoses bypass that safety catch entirely.
Where sunlight is genuinely insufficient, my preference is to look to the foods the nutrient naturally occupies before reaching for isolated high-dose tablets — and those foods are overwhelmingly animal foods. Oily fish are among the richest natural sources, with the interesting wrinkle that wild salmon carried several times the vitamin D of farmed salmon in one analysis (Ref 12). Egg yolks and liver contribute meaningfully; the vitamin travels with the fat, which is one more reason I am wary of advice that strips animal fat out of the diet. I am not persuaded that fortified plant foods are a like-for-like substitute for these sources, and I hold to that as a stated preference, not a proven hierarchy.
One physiological detail ties the food question back to the dosing question. Vitamin D is fat-soluble, and body fat acts as a reservoir that soaks it up: people with obesity achieve lower blood levels from the same intake because more of it is sequestered in fat tissue (Ref 13). That is the mundane explanation for a good deal of measured "deficiency", and it is also why any sensible intake is a function of the person, not a single national number — exactly the point the corrected statistics made from the other direction (Ref 4).
Should you get tested, and would it change anything?
A blood test is only worth doing if the result would change what you do. That is the filter I apply to every investigation, and 25(OH)D is a good case for it. For a broadly healthy person with reasonable sun exposure and a diet containing oily fish, eggs, and liver, a single number on a page is unlikely to change sensible behaviour, and the 2024 evidence review found no trial support for screening the general population (Ref 10). The situation is different if there is a real reason to suspect deficiency — very little sun exposure, living at high latitude, darker skin, obesity, malabsorption, being largely housebound, or symptoms that fit — because there the result can genuinely change management, and correcting a low level is the part of this whole story with the best evidence behind it (Ref 9).
I want to be careful not to talk over your own clinician here. General practitioners work within guidelines, finite time, and finite budgets, and interpreting a vitamin D level in the context of a whole person is exactly the kind of judgement they are trained for. If your level is genuinely low and symptomatic, that is worth acting on with them. If it is a borderline number in someone who feels well, the more useful question is usually how much sun and how much real food that person is getting, not which pill to add.
Conclusion
The story of the vitamin D recommendation is a good advertisement for reading the workings rather than the headline. A very widely used figure was built on a specific statistical error that understated its own target, and two independent groups agree the error was real (Ref 2, Ref 3). That genuinely should lower our confidence in tidy reference numbers. But the same discipline that exposes the error also restrains the conclusion: the corrected megadose figure was an extrapolation its own authors distrusted (Ref 2, Ref 4); moving a storage marker is not the same as improving health, and the trials that tested supplementation in healthy people came back null (Ref 6, Ref 7, Ref 8); and the benefit that does appear is concentrated in correcting genuine deficiency, not in chasing ever-higher levels (Ref 9). My own high-dose experiment is a single data point above the official limit and should be read as such. The position I actually hold is unglamorous: get sunlight where you can, eat the animal foods the nutrient lives in, correct real deficiency with a clinician rather than a target, and treat both the alarmist and the reassuring headlines about vitamin D with the same scepticism you would bring to the arithmetic behind them.
Disclosures
I run a private clinic and offer paid consultations, which is a commercial interest readers should weigh. I sell no vitamin D product and endorse no brand. I hold a stated dietary bias towards animal-source nutrition, disclosed above. I have described my own past use of high-dose vitamin D for transparency, not as advice. If you would like to discuss your own situation I am available, but for most people a good, regular relationship with a local clinician is worth more than any single consultation with me.
References
Identified and verified via PubMed; DOI links included.
Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. Journal of Clinical Endocrinology & Metabolism, 2011. https://doi.org/10.1210/jc.2010-2704
Veugelers PJ, Ekwaru JP. A statistical error in the estimation of the recommended dietary allowance for vitamin D. Nutrients, 2014. https://doi.org/10.3390/nu6104472
Heaney R, Garland C, Baggerly C, French C, Gorham E. Letter to Veugelers, P.J. and Ekwaru, J.P., A statistical error in the estimation of the recommended dietary allowance for vitamin D. Nutrients, 2015. https://doi.org/10.3390/nu7031688
Veugelers PJ, Pham TM, Ekwaru JP. Optimal Vitamin D Supplementation Doses that Minimize the Risk for Both Low and High Serum 25-Hydroxyvitamin D Concentrations in the General Population. Nutrients, 2015. https://doi.org/10.3390/nu7125527
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2011. https://doi.org/10.1210/jc.2011-0385
Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (the VITAL trial). New England Journal of Medicine, 2019. https://doi.org/10.1056/NEJMoa1809944
LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults (VITAL). New England Journal of Medicine, 2022. https://doi.org/10.1056/NEJMoa2202106
Neale RE, Baxter C, Romero BD, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes & Endocrinology, 2022. https://doi.org/10.1016/S2213-8587(21)00345-4
Sutherland JP, Zhou A, Hyppönen E. Vitamin D Deficiency Increases Mortality Risk in the UK Biobank: A Nonlinear Mendelian Randomization Study. Annals of Internal Medicine, 2022. https://doi.org/10.7326/M21-3324
Shah VP, Nayfeh T, Alsawaf Y, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D. Journal of Clinical Endocrinology & Metabolism, 2024. https://doi.org/10.1210/clinem/dgae312
Holick MF. Revisiting Vitamin D Guidelines: A Critical Appraisal of the Literature. Endocrine Practice, 2024. https://doi.org/10.1016/j.eprac.2024.10.011
Chen TC, Chimeh F, Lu Z, et al. (incl. Holick MF). Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Archives of Biochemistry and Biophysics, 2007. https://doi.org/10.1016/j.abb.2006.12.017
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. American Journal of Clinical Nutrition, 2000. https://doi.org/10.1093/ajcn/72.3.690
Levita J, Wilar G, Wahyuni I, et al. Clinical Toxicology of Vitamin D in Pediatrics: A Review and Case Reports. Toxics, 2023. https://doi.org/10.3390/toxics11070642
Chakraborty S, Sarkar AK, Bhattacharya C, Krishnan P, Chakraborty S. A nontoxic case of vitamin D toxicity. Laboratory Medicine, 2015. https://doi.org/10.1309/LM5URN1QIR7QBLXK
Hariri E, Kassis N, Iskandar JP, et al. Vitamin K – a neglected player in cardiovascular health: a narrative review. Open Heart, 2021. https://doi.org/10.1136/openhrt-2021-001715
Diederichsen ACP, Lindholt JS, Möller S, et al. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. Circulation, 2022. https://doi.org/10.1161/CIRCULATIONAHA.121.057008
Villa JKD, Diaz MAN, Pizziolo VR, Martino HSD. Effect of vitamin K in bone metabolism and vascular calcification: a review of mechanisms of action and evidences. Critical Reviews in Food Science and Nutrition, 2017. https://doi.org/10.1080/10408398.2016.1211616
Gröber U, Reichrath J, Holick MF, Kisters K. Vitamin K: an old vitamin in a new perspective. Dermato-endocrinology, 2015. https://doi.org/10.4161/19381972.2014.968490
